// App-Quantinova.ai

: Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH: Insights from TRITON

Researchers

Presenter

  • Olivier Sitbon

Principal Investigators

  • Nazzareno Galiè

  • Martin Doelberg

  • J Simon R Gibbs

  • Marius M Hoeper

  • Mylene Stefani

  • Stephen C Mathai

  • Vallerie Mclaughlin

  • Loïc Perchenet

  • Gérald Simonneau

  • Kelly Chin

Medical Centers

  • Hopital Bicetre, Universite Paris Sud, Le Kremlin Bicetre, France

  • Univeristy of Bologna, Bologna, Italy

  • Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

  • National Heart and Lung Institute, Imperial College London, London, United Kingdom

  • Medical School Hannover, German Center for Lung Research,, Hannover, Germany

  • Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, United States of America

  • University of Michigan - Ann Arbor - United States of America

  • UT Southwestern Medical Centre - Dallas - United States of America

Locations

  • France

  • Italy

  • Switzerland

  • United Kingdom

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Pulmonary arterial hypertension

Biomarkers

  • N/A

Drug/Treatment

  • macitentan

  • Tadalafil

  • Selexipag

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • NA

Study Id's

  • NCT02558231

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved